Risk Stratification of Pancreatic Ductal Adenocarcinoma Patients Undergoing Curative-Intent Surgery after Neoadjuvant Therapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Clinical prognostic criteria using preoperative factors were not developed for post–neoadjuvant therapy (NAT) surgery of pancreatic ductal adenocarcinoma (PDAC). We aimed to identify preoperative factors associated with overall survival (OS) in PDAC patients who underwent post-NAT curative-intent surgery and develop risk stratification criteria.Materials and Methods Consecutive PDAC patients who underwent post-NAT curative-intent surgeries between 2007 and 2020 were retrospectively analyzed. Demographic, laboratory, surgical, and histopathologic variables were collected. Baseline, preoperative, and interval changes of computed tomography (CT) findings proposed by the Society of Abdominal Radiology and the American Pancreatic Association were analyzed. Cox proportional hazard analysis was used to select preoperative variables associated with OS. We developed risk stratification criteria composed of the significant preoperative variables, i.e., post-NAT response criteria. We compared the discrimination performance of post-NAT response criteria with that of post-NAT pathological (yp) American Joint Cancer Committee TNM staging system.Results One hundred forty-five PDAC patients were included. Stable or increased tumor size on CT (hazard ratio [HR], 2.58; 95% confidence interval [CI], 1.58 to 4.21; p < 0.001) and elevated preoperative carbohydrate antigen 19-9 (CA19-9) level (HR, 1.98; 95% CI, 1.11 to 3.55; p=0.021) were independent factors of OS. The OS of the patient groups stratified by post-NAT response criteria which combined changes in tumor size and CA19-9 showed significant difference (p < 0.001). Such stratification was comparable to ypTNM staging in discrimination performance (difference of C-index, 0.068; 95% CI, –0.012 to 0.142).Conclusion “Any degree of decrease in tumor size on CT” and CA19-9 normalization or staying normal were independent favorable factors of OS. The combination of the two factors discriminated OS comparably to ypTNM staging.
Abstract
Purpose Clinical prognostic criteria using preoperative factors were not developed for post–neoadjuvant therapy (NAT) surgery of pancreatic ductal adenocarcinoma (PDAC). We aimed to identify preoperative factors associated with overall survival (OS) in PDAC patients who underwent post-NAT curative-intent surgery and develop risk stratification criteria.Materials and Methods Consecutive PDAC patients who underwent post-NAT curative-intent surgeries between 2007 and 2020 were retrospectively analyzed. Demographic, laboratory, surgical, and histopathologic variables were collected. Baseline, preoperative, and interval changes of computed tomography (CT) findings proposed by the Society of Abdominal Radiology and the American Pancreatic Association were analyzed. Cox proportional hazard analysis was used to select preoperative variables associated with OS. We developed risk stratification criteria composed of the significant preoperative variables, i.e., post-NAT response criteria. We compared the discrimination performance of post-NAT response criteria with that of post-NAT pathological (yp) American Joint Cancer Committee TNM staging system.Results One hundred forty-five PDAC patients were included. Stable or increased tumor size on CT (hazard ratio [HR], 2.58; 95% confidence interval [CI], 1.58 to 4.21; p < 0.001) and elevated preoperative carbohydrate antigen 19-9 (CA19-9) level (HR, 1.98; 95% CI, 1.11 to 3.55; p=0.021) were independent factors of OS. The OS of the patient groups stratified by post-NAT response criteria which combined changes in tumor size and CA19-9 showed significant difference (p < 0.001). Such stratification was comparable to ypTNM staging in discrimination performance (difference of C-index, 0.068; 95% CI, –0.012 to 0.142).Conclusion “Any degree of decrease in tumor size on CT” and CA19-9 normalization or staying normal were independent favorable factors of OS. The combination of the two factors discriminated OS comparably to ypTNM staging.
참고문헌 (32)
- Mokdad AA, "Neoadjuvant therapy followed by resec tion versus upfront resection for resectable pancreatic cancer : a propensity score matched analysis", J Clin Oncol, 35, pp.515~522 (2017)
- Janssen QP, "Neoadjuvant treatment in patients with resectable and bor derline resectable pancreatic cancer", Front Oncol, 10, pp.41~ (2020)
- Zhou Y, "Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy : a systematic review of the published lit erature", Updates Surg, 74, pp.43~53 (2022)
- Katz MH, "Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators", Cancer, 118, pp.5749~5756 (2012)
- Kim SS, "Retrospective evaluation of treatment response in patients with nonmeta static pancreatic cancer using CT and CA 19-9", Radiology, 303, pp.548~556 (2022)
- Yang HK, "Systematic review and meta-analysis of diagnostic perfor mance of CT imaging for assessing resectability of pancreatic ductal adenocarcinoma after neoadjuvant therapy : impor tance of CT criteria", Abdom Radiol(NY), 46, pp.5201~5217 (2021)
- Ishii H, "Primary tumor of pancreatic cancer as a measurable target lesion in chemotherapy trials", Jpn J Clin Oncol, 35, pp.601~606 (2005)
- Alvarez R, "Stromal disrupting effects of nab paclitaxel in pancreatic cancer", Br J Cancer, 109, pp.926~933 (2013)
- Truty MJ, "Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline", locally advanced pancreatic cancer, 2021, pp.273, 341~349
- Klaiber U, "Prognostic factors of survival after neoadjuvant treat ment and resection for initially unresectable pancreatic can cer", Ann Surg, 273, pp.154~162 (2021)
- Parra-Robert M, "Relationship between CA 19. 9 and the Lewis phe notype : options to improve diagnostic efficiency", Anticancer Res, 38, pp.5883~5888 (2018)
- Bockhorn M, "Borderline resectable pancreatic cancer : a consensus statement by the International Study Group of Pancreatic Surgery(ISGPS)", Surgery, 155, pp.977~988 (2014)
- "NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): pan creatic adenocarcinoma (version 2.2021)" (2021)[URL]
- Al-Hawary MM, "Pancreatic ductal adenocarcinoma radiol ogy reporting template : consensus statement of the society of abdominal radiology and the american pancreatic associa tion", Gastroenterology, 146, pp.291~304 (2014)
- Wang ZJ, "Therapeutic response assessment in pancre atic ductal adenocarcinoma : society of abdominal radiology review paper on the role of morphological and functional imaging techniques", Abdom Radiol(NY), 45, pp.4273~4289 (2020)
- Zins M, "Pancreatic adenocarcinoma staging in the era of preoperative chemotherapy and radia tion therapy", Radiology, 287, pp.374~390 (2018)
- Harrell FE Jr, "Multivariable prognostic models : issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors", Stat Med, 15, pp.361~387 (1996)
- Sim J, "The kappa statistic in reliability studies : use, interpretation, and sample size requirements", Phys Ther, 85, pp.257~268 (2005)
- Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- Barreto SG, "Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer", ANZ J Surg, 89, pp.481~487 (2019)
- van Veldhuisen E, "Added value of CA199 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy", HPB(Oxford), 20, pp.605~611 (2018)
- Reni M, "Selecting patients for resection after primary chemo therapy for non-metastatic pancreatic adenocarcinoma", Ann Oncol, 28, pp.2786~2792 (2017)
- Vestergaard EM, "Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secre tor genotypes and evaluation of secretor and Lewis genotyp ing in a Caucasian population", Clin Chem, 45, pp.54~61 (1999)
- Tempero MA, "Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer", Cancer Res, 47, pp.5501~5503 (1987)
- Mann DV, "Elevated tumour marker CA19-9 : clinical interpretation and influence of obstructive jaundice", Eur J Surg Oncol, 26, pp.474~479 (2000)
- Ong SL, "Elevation of carbohydrate antigen 19. 9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration", Dig Dis Sci, 53, pp.3213~3217 (2008)
- Luo G, "Potential biomarkers in Lewis negative patients with pancreatic cancer", Ann Surg, 265, pp.800~805 (2017)
- Kwon S, "Lewis antigen phenotype and survival of patients with pancreatic cancer", Pancreas, 49, pp.1348~1354 (2020)
- Zhao B, "Dynam ic change of serum CA19-9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas", BMC Cancer, 21, pp.517~ (2021)
- Ghaneh P, "The impact of positive resection margins on sur vival and recurrence following resection and adjuvant chem otherapy for pancreatic ductal adenocarcinoma", Ann Surg, 269, pp.520~529 (2019)
- Delpero JR, "Prognostic value of resection margin involvement after pancreaticoduodenectomy for ductal adenocarcinoma : updates from a French prospective multicenter study", Ann Surg, 266, pp.787~796 (2017)
- Cassinotto C, "Locally advanced pancreatic adenocarcinoma : reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy", Radiology, 273, pp.108~116 (2014)